England’s National Health Service reached a deal to pay for U.S. drugmaker Biogen Inc.’s expensive spinal muscle atrophy treatment Spinraza.
Novartis said claims of price fixing against the drugmaker’s Sandoz generics unit amid a U.S. probe of 20 drugmakers are without merit, with the Swiss company vowing to fight allegations in a lawsuit.
Eli Lilly and Co. pulled ahead in a three-way race with Amgen Inc. and Teva Pharmaceutical Industries Ltd. in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that the company’s therapy can completely prevent headaches in a small percentage of patients.
U.S. President Donald Trump slammed the pharmaceutical industry for high prices of prescription drugs and vowed to allow U.S. states to buy medicines from other countries if they cost less.
The Trump administration will require drugmakers to disclose the list price of prescription drugs in DTC TV advertisements, part of the government’s efforts to lower costs for U.S. consumers.
Amgen Inc. set the U.S. list price for the company’s new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.
ViiV Healthcare presented three-year data from the SWORD 1 and 2 clinical trials in HIV.
Bayer AG and Johnson & Johnson agreed to settle more than 25,000 U.S. lawsuits over the companies’ blockbuster blood thinner Xarelto for a total of $775 million, court documents showed.
AbbVie’s Humira, the world’s top-selling prescription medicine since 2012, brought the Illinois-based company nearly $20 billion in revenue in 2018.
Drugmaker Eli Lilly and Co. announced plans to sell a half-price version of the company’s popular insulin injection Humalog.